Navigation Links
Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
Date:4/2/2008

MACCLESFIELD, England, April 2 /PRNewswire-FirstCall/ -- Today, (2nd April 2008), Cyprotex announces that it is introducing a new product line, Cloe(R) Select. Cloe(R) Select is a portfolio of bespoke studies which can be customised to individual customer requirements. It complements the current range of Cloe(R) Screen assays to provide ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic solutions from early discovery through to later stage development projects. As with Cloe(R) Screen, Cloe(R) Select meets the criteria set by the regulatory guidelines to provide constant confidence in the quality of the data.

The drug discovery and development process represents a number of pre-clinical phases which cover hit to lead, lead optimization and candidate selection. Cyprotex can now offer a fully integrated solution in the area of ADME and pharmacokinetics throughout this entire process. We have gained extensive knowledge in our field over the past 9 years, which is attributed to investing in high caliber committed scientists and by working with a large and diverse customer base.

Mr. Robert Atwater, Cyprotex's Chief Executive Officer, comments on the launch of this new product line. "Many of our customers rely on us for their ADME projects right from early screening projects through to IND submission. Building these relationships and ensuring that we can offer a flexible and broad range of screening options has been critical in the success of our business."

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. Our unique Cloe(R) Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. Introducing Cloe(R) Select ensures that Cyprotex can extend their offering to later stage more in-depth studies which require a more flexible approach. Cyprotex also has extensive expertise in physiologically based pharmacokinetic (PB-PK) modelling and quantitative structure activity relationship (QSAR) modelling techniques under its Cloe(R) Predict service. In combination, Cloe(R) Screen, Cloe(R) Select and Cloe(R) Predict offer an integrated solution for both experimental screening and prediction, fulfilling the needs of our broad and varied customer base.

For further information:

Cyprotex PLC,

Helen Gill PhD, Product Development Manager,

Tel: +44-1625-505-100,

h.gill@cyprotex.com.

http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
3. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
4. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
5. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
6. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
7. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
8. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery
11. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... of the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment ... be validating these new tools and assays, and their applicability in drug safety ...
(Date:1/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... initiated a global Phase 2b induction study in ... targets alpha4beta7 integrin. The aim of this randomized, ... the safety/tolerability and efficacy of PTG-100 in approximately ... severe active disease. "We are ...
(Date:1/16/2017)...   Valentin A. Pavlov, PhD , associate investigator, ... CEO of The Feinstein Institute for Medical Research ... the nervous system regulates the immune system, which will ... devices to treat disease and injury. The analysis ... The paper examines various studies which further define ...
(Date:1/14/2017)... ... 14, 2017 , ... Seattle-based Phase Genomics has announced the ... researchers around the globe. Long considered a “holy grail” in biological research, ... of scientific questions. The announcement was made today at the Plant & ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
Breaking Biology News(10 mins):